San Francisco · CA, USA; Berkeley, CA, USA · founded 2019 · https://www.millionmarker.com/
Diligence memoA one-page analyst read on Million Marker — recommendation, valuation, rhythm, risks.→Million Marker: limited disclosed financing to assess.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
23andMe for environmental exposures
We are a service for people to learn about their personal environmental exposures. Our first product is a urine test for exposure to chemicals in everyday products.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
No round amounts on record to chart.
No staged rounds to sequence.
Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 8525 companies in this sector. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 96% of sector peers (real $). Modeled value above 96% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| No rounds recorded. | |||||
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Million Marker is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Measured Telemedicine platform for chronic conditions like obesity | Healthtech | — | — | 72% |
| Starling AI enabling digital urine diagnostics in the home | Medical Devices | — | — | 71% |
| BillionToOne The genetic testing platform detecting and measuring disease. | Pharma | — | — | 71% |
| Spot Health At-home diagnostics as a service | Medical Devices | — | — | 70% |
| 23andMe, Inc. 23andMe is a saliva-based DNA service. We provide genetic reports on your ancestry, family history and help you connect with your DNA relatives. | Other Technology | Series D+ | $2.3B | 69% |
| InnaMed At-home blood testing: measure + analyze + enhance. | Biotech | — | — | 69% |
| Biobot Analytics, Inc. Population health analytics powered by wastewater. | Software / Tech | Series B | $73.4M | 69% |
| Marker Therapeutics, Inc. | Biotechnology | Series B | $93.4M | 69% |
See where Million Marker sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Million Marker, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.